TERT and cancer: This proportion was in line with our previous findings, and with the overall prevalence of tumour-infiltrative lymphocyte (TIL) positivity identified in many human cancers.14 The frequency of patients with circulating anti-TERT Th1 immunity decreased with NSCLC progression, being only 24% among metastatic stage IV compared with 45% and 55% in localised I–III and I–II stages, respectively.